STOCK TITAN

Jazz Pharmaceuticals plc - JAZZ STOCK NEWS

Welcome to our dedicated news page for Jazz Pharmaceuticals plc (Ticker: JAZZ), a resource for investors and traders seeking the latest updates and insights on Jazz Pharmaceuticals plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Jazz Pharmaceuticals plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Jazz Pharmaceuticals plc's position in the market.

Rhea-AI Summary
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) receives positive CHMP opinion for marketing authorization of JZP458 for the treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma. The European Medicines Agency's Committee for Medicinal Products for Human Use recommends approval of JZP458 as a component of a multi-agent chemotherapeutic regimen for patients with hypersensitivity to E. coli-derived asparaginase.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.2%
Tags
none
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.04%
Tags
none
Rhea-AI Summary
Jazz Pharmaceuticals will participate in the 2023 Goldman Sachs Global Healthcare Conference. The company's management will have a fireside chat on June 13, 2023. An audio webcast of the chat will be available on the Jazz Pharmaceuticals website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.04%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.29%
Tags
conferences
-
Rhea-AI Summary
Jazz Pharmaceuticals reported 1Q23 total revenues of $892.8 million, a 10% increase compared to 1Q22. Net product sales of Xywav increased by 49%, Epidiolex/Epidyolex increased by 20%, and Rylaze increased by 58% compared to the same period last year. The company is confident in the blockbuster potential of Epidiolex and expects continued strong demand. Jazz Pharmaceuticals also highlighted its enhanced pipeline, which is expected to deliver at least three late-stage data readouts by the end of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.41%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.3%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.8%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.8%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.07%
Tags
conferences
Jazz Pharmaceuticals plc

Nasdaq:JAZZ

JAZZ Rankings

JAZZ Stock Data

6.89B
60.45M
2.82%
95.89%
5.23%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Ireland
Dublin

About JAZZ

jazz pharmaceuticals plc (nasdaq: jazz) is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing meaningful products that address unmet medical needs. we are a diverse company of over 875 employees focused on portfolio of products and/or product candidates in the areas of sleep, hematology/oncology and pain. founded in 2003 and headquartered in dublin, ireland, jazz pharmaceuticals has u.s. offices in palo alto, ca and philadelphia, pa, and has offices in various other locations in europe. the company’s maintains a highly collaborative and entrepreneurial culture where employees focus on how they accomplish success as well as what is done to accomplish results by operating in accordance with the company’s core values: integrity, collaboration, passion, innovation and the pursuit of excellence. we plan to build upon our portfolio of products through acquisition and/or in-licensing activities, and leveraging our uni